Table 1. Baseline characteristics.
| Sitagliptine | Other glucose‐lowering agents | P‐value | |
|---|---|---|---|
| Males/females | 26/16 | 18/20 | 0.140 |
| Age (years) | 63.9 ± 12.7 | 64.5 ± 11.0 | 0.954 |
| Duration of DM (years) | 10.0 ± 6.7 | 8.8 ± 6.5 | 0.405 |
| Bodyweight (kg) | 68.0 ± 13.2 | 63.5 ± 13.4 | 0.053 |
| Body mass index (kg/m2) | 25.2 ± 4.2 | 25.3 ± 4.1 | 0.981 |
| SBP (mmHg) | 126.6 ± 11.9 | 120.3 ± 8.8 | 0.024 |
| DBP (mmHg) | 72.2 ± 9.0 | 68.7 ± 7.6 | 0.098 |
| HbA1c (%) | 7.0 ± 0.7 | 6.9 ± 0.7 | 0.688 |
| FPG (mg/dL) | 138.1 ± 21.4 | 131.5 ± 26.0 | 0.103 |
| FPI (μg/mL) | 5.8 ± 3.6 | 6.9 ± 5.7 | 0.769 |
| HOMA‐IR | 2.0 ± 1.4 | 2.4 ± 2.3 | 0.696 |
| HOMA‐β (%) | 29.3 ± 19.4 | 37.0 ± 26.5 | 0.236 |
| LDL‐C (mg/dL) | 109.8 ± 29.4 | 103.7 ± 25.8 | 0.226 |
| HDL‐C (mg/dL) | 68.2 ± 16.2 | 62.8 ± 15.2 | 0.188 |
| TG (mg/dL) | 98.9 ± 41.7 | 112.1 ± 66.9 | 0.596 |
| eGFR (mL/min/1.73 m2) | 77.1 ± 18.9 | 75.5 ± 28.1 | 0.399 |
| Serum creatinine (mg/dL) | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.172 |
| Urine albumin (mg/gCre) | 61.4 ± 154.3 | 61.4 ± 154.3 | 0.762 |
| Log (urine albumin) | 1.3 ± 0.7 | 1.2 ± 0.6 | 0.762 |
| ACE‐inhibitors or ARBs | 18 (42.9) | 14 (36.8) | 0.375 |
| Statins | 20 (47.6) | 21 (55.3) | 0.323 |
| Diabetes therapy | |||
| Pioglitazone (mg/day) | 24.6 ± 7.3 | 23.3 ± 7.6 | 0.414 |
| Sulfonylurea | 16 (38.1) | 15 (39.5) | 0.541 |
Data are mean ± standard deviation, or n (%). Differences between groups were tested by Mann–Whitney U‐test; categorical values were tested by χ2‐test. ACE, angiotensin converting enzyme; ARB, angiotensin‐receptor blockers; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; FPI, fasting plasma insulin; HbA1c, hemoglobin A1c; HOMA‐β, homeostasis model assessment β cell function; HOMA‐IR, homeostasis assessment model of insulin resistance; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride.